Stocks Stuck in Neutral After Hitting All-Time Highs

Stock markets are stuck in neutral today after ending last week at an all-time record close. As of 3:15 p.m. EDT the Dow Jones Industrial Average (DJINDICES: ^DJI  ) is down a negligible three points, while the S&P 500 (SNPINDEX: ^GSPC  ) is up a fraction of a point.

Among Dow stocks, shares of Cisco (NASDAQ: CSCO  ) have made one of the biggest moves, dropping 1.3%. The company reported strong earnings last week, but the stock may have gotten ahead of fundamentals as investors got excited about an earnings beat in the network space. Today an analyst at R. W. Baird downgraded Cisco's FlexPod partner NetApp to neutral and said Cisco was unlikely to buy the firm. This news doesn't justify a big drop in the stock, but after the stock's run-up last week, a slight pullback comes as no surprise. 

Consumer staple company Procter & Gamble (NYSE: PG  ) is another big loser on the Dow today, falling 1.2%. The company filed a patent infringement lawsuit against CAO Group in an Ohio court today, alleging the infringement of a number of dental products. The suit centers on CAO products that compete with Crest Whitestrips, which marked P&G as an innovator in a new market. Such actions are common in areas protected heavily by intellectual property, and P&G is just trying to protect a prized business, so there's no need to panic today. 

Merck (NYSE: MRK  ) rounds out the three Dow stocks losing big-time today, falling 1.9% to lead the index lower. The FDA released a review of the company's new sleep aid, finding it to be effective but noting some troubling side effects. Daytime drowsiness, suicidal thinking, and driving issues were cited in the report -- not side effects that Merck and its investors are happy about. The FDA will ask a panel of experts to vote on the safety and effectiveness of the drug, and it appears that higher dosing levels will be on the chopping block first. 

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons both to buy and to sell. To find out more, click here to claim your copy today.



Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2441969, ~/Articles/ArticleHandler.aspx, 8/21/2014 2:41:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement